News articles about T2 Biosystems (NASDAQ:TTOO) have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. T2 Biosystems earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the medical equipment provider an impact score of 46.2477306061294 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Analysts Expect T2 Biosystems Inc (TTOO) Will Post Quarterly Sales of $1.15 Million (americanbankingnews.com)
- T2 Biosystems Inc (TTOO) Expected to Post Earnings of -$0.42 Per Share (americanbankingnews.com)
- Wedbush Reiterates a “Hold” Rating on Nike (NKE) and $57.0 Target; Last Week T2 Biosystems, Inc. (TTOO) Analysts – Hill Country Times (hillcountrytimes.com)
- T2 Biosystems Inc (TTOO) Given Consensus Recommendation of “Hold” by Analysts (americanbankingnews.com)
Several research analysts have commented on the company. Zacks Investment Research raised T2 Biosystems from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research report on Wednesday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of T2 Biosystems in a research report on Friday, November 3rd. Canaccord Genuity reaffirmed a “buy” rating and set a $6.00 price target on shares of T2 Biosystems in a research report on Monday, October 30th. Finally, ValuEngine upgraded T2 Biosystems from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 13th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. T2 Biosystems presently has a consensus rating of “Hold” and an average target price of $6.54.
T2 Biosystems (NASDAQ:TTOO) last announced its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.04. T2 Biosystems had a negative return on equity of 244.82% and a negative net margin of 1,497.70%. The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $1.10 million. The firm’s revenue for the quarter was up 2.8% compared to the same quarter last year. equities analysts expect that T2 Biosystems will post -1.85 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect T2 Biosystems (TTOO) Share Price” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://sportsperspectives.com/2017/12/19/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-t2-biosystems-ttoo-share-price.html.
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.